Three researchers from Manchester Biomedical Research Centre (BRC) have been appointed Senior Investigators by the National Institute for Health Research (NIHR).
The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.
Professor Paul Dark, Non-fungal Infections Programme Lead, is one of the authors of the paper “Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19,” recently published in JAMA.
A study of tuberculosis (TB) patients in six Jakarta hospitals has revealed up to 13 per cent of them had fungal lung infection – or aspergillosis – at the end of their treatment.
Dr Alexander Mathioudakis, Respiratory Theme Researcher, and John Linnell, patient participant, discuss an international study that will revolutionise the way COPD exacerbation research outcomes are evaluated and how this could benefit COPD patients in the future.
Jemma Haines, NIHR Manchester Biomedical Research Centre PhD Fellow has been awarded an MBE in the Queen’s birthday honours list.
A study by NIHR Manchester Biomedical Research Centre (BRC) researchers has found patients with a common respiratory disease had more flare-ups linked to activities that put them at risk of being exposed to mould.
Professor Paul Dark, NIHR Manchester Biomedical Research Centre (BRC) Respiratory Non-fungal Infections Programme Lead has been appointed to a key role in the National Institute for Health Research (NIHR).